Literature DB >> 12385578

The promoter polymorphism of the matrix metalloproteinase 3 (MMP-3) gene in women with ovarian cancer.

K Szyllo1, B Smolarz, H Romanowicz-Makowska, M Niewiadomski, E Kozlowska, A Kulig.   

Abstract

Matrix metalloproteinases (MMPs) comprise family proteolytic enzymes that degrade extracellular matrix components and therefore play an important role in tumour cell invasion and cancer metastasis. Overexpression of matrix metalloproteinase 3 (MMP-3 or stromelysin 1) gene has been demonstrated in various types of cancers and high level of MMP-3 protein in tumour is a poor prognostic factor for patients. The insertion (6A)/deletion (5A) polymorphism (5A/6A polymorphism) located at the promoter of the MMP-3 gene may have functional significance in the regulation of its expression. In the present work the distribution of genotypes and frequencies of alleles of the 5A/6A polymorphism in subjects with ovarian cancer were investigated. Paraffin embedded tumour tissues were obtained from 100 women with ovarian cancer. The genotypes of 5A/6A polymorphism were determined by PCR amplification using the allele specific primers. The distribution of the genotypes of the 5A/6A polymorphism in both control and patients did not differ significantly (p > 0.05) from those predicted by the Hardy-Weinberg distribution. Additionally, there were no significant differences (p > 0.05) in genotype distributions and allele frequencies between subgroups assigned to histological stage. The results suggest that the 5A/6A polymorphism of MMP-3 gene may not be linked with appearance and development to ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12385578

Source DB:  PubMed          Journal:  J Exp Clin Cancer Res        ISSN: 0392-9078


  5 in total

1.  Molecular regulation of ovarian cancer cell invasion.

Authors:  Ningxia Sun; Qing Zhang; Chen Xu; Qian Zhao; Yan Ma; Xinmei Lu; Liang Wang; Wen Li
Journal:  Tumour Biol       Date:  2014-08-15

Review 2.  Cellular apoptosis susceptibility (CSE1L/CAS) protein in cancer metastasis and chemotherapeutic drug-induced apoptosis.

Authors:  Cheng-Jeng Tai; Chung-Huei Hsu; Shing-Chuan Shen; Woan-Ruoh Lee; Ming-Chung Jiang
Journal:  J Exp Clin Cancer Res       Date:  2010-08-11

3.  Tissue transglutaminase regulates matrix metalloproteinase-2 in ovarian cancer by modulating cAMP-response element-binding protein activity.

Authors:  Minati Satpathy; Minghai Shao; Robert Emerson; David B Donner; Daniela Matei
Journal:  J Biol Chem       Date:  2009-03-26       Impact factor: 5.157

4.  Polymorphisms in the matrix metalloproteinase-1, 3, and 9 promoters and susceptibility to adult astrocytoma in northern China.

Authors:  Zhongqiang Lu; Yanyan Cao; Yimin Wang; Qingjun Zhang; Xianghong Zhang; Shuheng Wang; Yuehong Li; Huiling Xie; Baohua Jiao; Jianhui Zhang
Journal:  J Neurooncol       Date:  2007-05-15       Impact factor: 4.130

Review 5.  Association between matrix metalloproteinases polymorphisms and ovarian cancer risk: A meta-analysis and systematic review.

Authors:  Xu-Ming Zhu; Wei-Feng Sun
Journal:  PLoS One       Date:  2017-09-28       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.